Acute Spinal Cord Injury - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 52 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Acute Spinal Cord Injury - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Acute Spinal Cord Injury - Pipeline Review, H2 2014', provides an overview of the Acute Spinal Cord Injury's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Spinal Cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Spinal Cord Injury and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Spinal Cord Injury
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acute Spinal Cord Injury and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acute Spinal Cord Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Spinal Cord Injury pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Spinal Cord Injury
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Spinal Cord Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Acute Spinal Cord Injury Overview 6
Therapeutics Development 7
Pipeline Products for Acute Spinal Cord Injury - Overview 7
Pipeline Products for Acute Spinal Cord Injury - Comparative Analysis 8
Acute Spinal Cord Injury - Therapeutics under Development by Companies 9
Acute Spinal Cord Injury - Therapeutics under Investigation by Universities/Institutes 10
Acute Spinal Cord Injury - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Acute Spinal Cord Injury - Products under Development by Companies 13
Acute Spinal Cord Injury - Products under Investigation by Universities/Institutes 14
Acute Spinal Cord Injury - Companies Involved in Therapeutics Development 15
Acorda Therapeutics, Inc. 15
Kringle Pharma, Inc. 16
Neuralstem, Inc. 17
Neuronax SAS 18
Acute Spinal Cord Injury - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
AC-105 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
BA-210 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Cell Therapy for Spinal Cord Injury - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
KP-100IT - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
NSI-566 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
NX-210 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Peptide to Inhibit Ephrin-A for ALS and Acute Spinal Cord Injury - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Peptides to Inhibit Major Histocompatibility Complex Class I and II for Central Nervous System and Musculoskeletal Disorders - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Stem Cell Therapy for Acute Spinal Cord Injury - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Acute Spinal Cord Injury - Recent Pipeline Updates 41
Acute Spinal Cord Injury - Dormant Projects 49
Acute Spinal Cord Injury - Product Development Milestones 50
Featured News & Press Releases 50
Nov 26, 2013: NX210 receives Orphan Drug Designation in Europe for the treatment of spinal cord injuries 50
Jan 24, 2013: Acorda Therapeutics Announces Department Of Defense Contract To Support Study Of AC105 In Acute Spinal Cord Injury 50
Oct 15, 2012: Neuronax receives 600.000 euros from Oseo to support its NX210 Project 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
Number of Products under Development for Acute Spinal Cord Injury, H2 2014 7
Number of Products under Development for Acute Spinal Cord Injury - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Acute Spinal Cord Injury - Pipeline by Acorda Therapeutics, Inc., H2 2014 15
Acute Spinal Cord Injury - Pipeline by Kringle Pharma, Inc., H2 2014 16
Acute Spinal Cord Injury - Pipeline by Neuralstem, Inc., H2 2014 17
Acute Spinal Cord Injury - Pipeline by Neuronax SAS, H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Acute Spinal Cord Injury Therapeutics - Recent Pipeline Updates, H2 2014 41
Acute Spinal Cord Injury - Dormant Projects, H2 2014 49